NCT02200445View on ClinicalTrials.gov

Low Dose IL-2 for Ulcerative Colitis

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

October 1, 2020

Study Completion Date

March 31, 2021

Conditions
Ulcerative Colitis
Interventions
DRUG

Interleukin-2 (aldesleukin).

"Description of intervention is covered in Arm, above."

Trial Locations (2)

02115

Boston Children's Hospital, Boston

Brigham & Women's Hospital, Boston

All Listed Sponsors
lead

Scott B. Snapper, MD PHD

OTHER

NCT02200445 - Low Dose IL-2 for Ulcerative Colitis | Biotech Hunter | Biotech Hunter